Sibutramine is a centrally acting anorexiant formerly used in the management of obesity , particularly in patients with a BMI ≥30 kg/m² or ≥27 kg/m² with comorbid conditions (e.g., type 2 diabetes, dyslipidemia, or hypertension). It was withdrawn in many countries , including the U.S. and EU, due to increased cardiovascular risks.
Mechanism of Action
- Centrally acting sympathomimetic agent.
- Inhibits the reuptake of serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in the hypothalamus.
- Increases satiety and decreases appetite.
- Secondary effects: Enhances thermogenesis and increases energy expenditure via sympathetic stimulation.
Clinical Effects
- Promotes dose-dependent weight loss .
- Reduces waist circumference and visceral fat .
- Improves lipid profile:
- ↓ Triglycerides, ↓ VLDL
- ↑ HDL
- Enhances insulin sensitivity and glucose metabolism .
NOTE:
Due to adverse cardiovascular effects , sibutramine has been withdrawn from most markets (FDA withdrawal in 2010).
Pharmacokinetics
- Route : Oral
- Absorption : Well-absorbed, undergoes first-pass metabolism in the liver.
- Active Metabolites : Desmethylsibutramine and didesmethylsibutramine.
- Elimination : Metabolites excreted in urine (85%) and feces .
- Half-life : Active metabolites ~14–16 hours.
Dosage
| Patient Group | Recommended Dose |
|---|---|
| Adults | Initial: 10 mg once daily. May increase to 15 mg/day after 4 weeks if no adequate response. |
| Special cases | 5 mg for patients intolerant to 10 mg |
| Max dose | 15 mg/day |
| Pediatrics | Not approved for <16 years |
Indications
- Adjunct to a reduced-calorie diet for:
- Obese adults (BMI ≥30)
- Overweight adults (BMI ≥27) with associated risk factors.
Contraindications
- Uncontrolled hypertension
- Cardiovascular diseases : CAD, CHF, arrhythmias, stroke
- Hyperthyroidism
- Glaucoma
- History of eating disorders
- MAOI use within 14 days
- Pregnancy and lactation
- Age <16 years
Precautions
- Regular BP and HR monitoring .
- Avoid in patients with renal impairment or hepatic dysfunction .
- Monitor for psychiatric symptoms : agitation, depression, suicidal ideation.
- Abuse potential : May cause tolerance and dependence .
Adverse Effects
Common:
- Dry mouth
- Constipation
- Insomnia
- Headache
- Increased BP and HR
Serious:
- Seizures
- Arrhythmias
- Hypertensive crisis
- Serotonin syndrome (when combined with SSRIs, SNRIs, MAOIs, or triptans)
- Psychiatric symptoms : depression, agitation, suicidal thoughts
Drug Interactions
- SSRIs, SNRIs, MAOIs → ↑ risk of serotonin syndrome
- CYP3A4 inhibitors/inducers → altered sibutramine metabolism
- Triptans, ergotamine , decongestants → ↑ hypertensive risk
- St. John’s Wort and other serotonergic agents should be avoided
Use in Pregnancy and Lactation
- Pregnancy Category C
- Not recommended during pregnancy or breastfeeding
- Effective contraception advised during use
Pediatric Use
- Not recommended for patients <16 years due to increased psychiatric side effects and lack of safety data
Availability
Note : Sibutramine has been withdrawn in many regions
Previously available as capsules :
- 5 mg
- 10 mg
- 15 mg
Evidence-Based Findings
- A meta-analysis (Padwal et al., 2003) reported:
- 4.6% mean weight loss over one year
- 15% of patients lost ≥10% of body weight
- Significant improvements in lipid profile and waist circumference
